The Latest Analyst Ratings For Penumbra

Loading...
Loading...

In the latest quarter, 7 analysts provided ratings for Penumbra PEN, showcasing a mix of bullish and bearish perspectives.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 3 1 0 0
Last 30D 0 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 1 1 0 0 0
3M Ago 2 2 1 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $281.86, a high estimate of $290.00, and a low estimate of $250.00. This current average has decreased by 4.39% from the previous average price target of $294.80.

Decoding Analyst Ratings: A Detailed Look

A clear picture of Penumbra's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Matt O'Brien Piper Sandler Maintains Overweight $290.00 $290.00
Richard Newitter Truist Securities Lowers Buy $280.00 $290.00
Matt O'Brien Piper Sandler Lowers Overweight $290.00 $310.00
Shagun Singh RBC Capital Maintains Outperform $289.00 -
William Plovanic Canaccord Genuity Maintains Buy $284.00 -
David Rescott Truist Securities Lowers Buy $290.00 $300.00
Robbie Marcus JP Morgan Lowers Neutral $250.00 $284.00

Key Insights:

  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Penumbra. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Penumbra compared to the broader market.
  • Price Targets: Delving into movements, analysts provide estimates for the future value of Penumbra's stock. This analysis reveals shifts in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Penumbra's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Penumbra analyst ratings.

Unveiling the Story Behind Penumbra

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.

Understanding the Numbers: Penumbra's Finances

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Positive Revenue Trend: Examining Penumbra's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 28.69% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: Penumbra's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 19.05%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Penumbra's ROE excels beyond industry benchmarks, reaching 4.75%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Penumbra's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.58%, the company showcases efficient use of assets and strong financial health.

Debt Management: Penumbra's debt-to-equity ratio is below the industry average. With a ratio of 0.2, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

The Basics of Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...